Status:
UNKNOWN
Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression
Lead Sponsor:
University of Arizona
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
New Onset Diabetes After Transplant
Kidney Transplantation
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
This study is being conducted to determine if belatacept is an appropriate alternative immunosuppressive medication (reducing the immune system's effect) when a kidney transplant patient develops new ...
Eligibility Criteria
Inclusion
- Written informed consent must be given by patient.
- Adult patients between age 18 and 65
- Thymoglobulin induction at the time of transplant
- Patient must be Epstein-Barr Virus seropositive
Exclusion
- Patient who received an blood type incompatible transplant, or with T-cell or B-cell positive crossmatch
- Patients with Hepatitis B, Hepatitis C, HIV or a clinically significant systemic infection within 30 days prior to transplant
- History of stroke, severe cardiac disease or cardiac failure
Key Trial Info
Start Date :
August 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2016
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT01875224
Start Date
August 1 2013
End Date
August 1 2016
Last Update
June 11 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Arizona
Tucson, Arizona, United States, 85724